Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit

PHASE4CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

June 6, 2023

Study Completion Date

June 6, 2023

Conditions
Cystic Fibrosis Gastrointestinal Disease
Interventions
DRUG

Polyethylene Glycol 3350

All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.

DEVICE

SmartPill Motility System & PillCam Patency Capsule

Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.

Trial Locations (2)

63104

SSM Health Cardinal Glennon Children's Hosptial, St Louis

SSM Health Saint Louis University Hosptial, St Louis

All Listed Sponsors
lead

St. Louis University

OTHER

NCT04210427 - Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit | Biotech Hunter | Biotech Hunter